Chiara Orlacchio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chiara Orlacchio has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Bohan Zhang
Laboratory of Epigenetics and Neuroendocrinology, Institute for Neuroscience, Department of Health Science and Technology, ETH Zürich
1 shared publication - Erick Moran Carreira
ETH Zurich
1 shared publication - Karina M. Hugentobler
Laboratory of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich, Zürich, Switzerland
1 shared publication - Katharina Gapp
D-HEST Institute for Neurosciences, ETH Zürich, Street, Zürich, 100190, Switzerland
1 shared publication - Mahshid Gazorpak
Laboratory of Epigenetics and Neuroendocrinology, Institute for Neuroscience, Department of Health Science and Technology, ETH Zürich
1 shared publication Miriam Kretschmer
Laboratory of Epigenetics and Neuroendocrinology, Institute for Neuroscience, Department of Health Science and Technology, ETH Zürich
1 shared publication
Latest Publications
- Open Access
- 21 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Light-controlled disruption of cancer cell dormancy via photoswitchable stress hormone receptor degraders
Cancer cell dormancy is a key contributor to therapy resistance and disease relapse. The glucocorticoid receptor (GR), a major mediator of stress hormone signaling, has emerged as a central regulator of dormancy in non-lymphoid solid tumors, particularly lung cancer. However, systemic GR inhibition or degradation using conventional Proteolysis Targeting Chimeras (PROTACs) risks widespread on-target toxicity due to their constitutive activity. We hypothesized that integrating photoswitchable elements into PROTACs, termed photoPROTACs, would enable wavelength-specific, spatiotemporally precise modulation of GR degradation and dormancy-associated signaling pathways. Here, we synthesized a diverse series of photoPROTACs incorporating photoswitchable arylazotriazole or arylazopyrazole scaffolds, including previously unreported (OEt) 2 - and (NMe 2 ) 2 -substituted photoswitches. Arylazopyrazole-based GR photoPROTACs bearing Me 2 - and (OEt) 2 substituents exhibited near-quantitative photoisomerization (95% Z- isomer; 89 to 92% E- isomer), no photobleaching, and thermal half-lives in the range of 3 to 12.2 d in dimethyl sulfoxide (DMSO). Among them, KH-5-306 and KH-5-309 induced potent, specific, and reversible GR degradation in their thermodynamically stable E- isomeric form at low nanomolar concentrations, with markedly reduced activity in the Z- isomeric state. Transcriptomic profiling showed that E- KH-5-309 disrupts GR-driven dormancy-associated gene expression programs in a non–small cell lung cancer (NSCLC) model, while the Z- isomer remains functionally inert. Our findings establish a framework for the rational design of photoswitchable PROTACs beyond GR and demonstrate their potential to achieve spatiotemporal control of stress hormone receptor signaling, enabling mechanistic insights into GR function and the targeted disruption of cancer cell dormancy.
- 21 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Open AccessLight-controlled disruption of cancer cell dormancy via photoswitchable stress hormone receptor degraders
Cancer cell dormancy is a key contributor to therapy resistance and disease relapse. The glucocorticoid receptor (GR), a major mediator of stress hormone signaling, has emerged as a central regulator of dormancy in non-lymphoid solid tumors, particularly lung cancer. However, systemic GR inhibition or degradation using conventional Proteolysis Targeting Chimeras (PROTACs) risks widespread on-target toxicity due to their constitutive activity. We hypothesized that integrating photoswitchable elements into PROTACs, termed photoPROTACs, would enable wavelength-specific, spatiotemporally precise modulation of GR degradation and dormancy-associated signaling pathways. Here, we synthesized a diverse series of photoPROTACs incorporating photoswitchable arylazotriazole or arylazopyrazole scaffolds, including previously unreported (OEt) 2 - and (NMe 2 ) 2 -substituted photoswitches. Arylazopyrazole-based GR photoPROTACs bearing Me 2 - and (OEt) 2 substituents exhibited near-quantitative photoisomerization (95% Z- isomer; 89 to 92% E- isomer), no photobleaching, and thermal half-lives in the range of 3 to 12.2 d in dimethyl sulfoxide (DMSO). Among them, KH-5-306 and KH-5-309 induced potent, specific, and reversible GR degradation in their thermodynamically stable E- isomeric form at low nanomolar concentrations, with markedly reduced activity in the Z- isomeric state. Transcriptomic profiling showed that E- KH-5-309 disrupts GR-driven dormancy-associated gene expression programs in a non–small cell lung cancer (NSCLC) model, while the Z- isomer remains functionally inert. Our findings establish a framework for the rational design of photoswitchable PROTACs beyond GR and demonstrate their potential to achieve spatiotemporal control of stress hormone receptor signaling, enabling mechanistic insights into GR function and the targeted disruption of cancer cell dormancy.